+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hormonal Contraceptive Market Size, Share & Trends Analysis Report By Method (Pill, Intrauterine Device (IUD), Patch, Implant, Vaginal Ring, Injectable), By Region, And Segment Forecasts, 2019 - 2026

  • ID: 4538762
  • Report
  • Region: Global
  • 100 Pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • Afaxys, Inc.
  • Agile Therapeutics
  • Allergan
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer
  • MORE

The global hormonal contraceptive market size is expected to reach USD 27.5 billion by 2026, based on this report. It is projected to register a CAGR of 4.1% during the forecast period. Introduction of innovative products and growing awareness about reproductive and sexual health in emerging regions are likely to drive the growth.

Pill, Intrauterine Devices (IUD), injectable, vaginal rings, implants, and patches are various methods used for hormonal contraception. Hormonal contraception methods act on the endocrine system to prevent ovulation. Increasing number of women in developing economies are using contraceptives due to the rise in government initiatives and programs. This factor is anticipated to accelerate the market growth. For instance, according to the UN, approximately 64.0% of women between 15 and 49 years of age were using some form of family planning in 2015, be it traditional or modern. This figure stood at 36.0% in 1970.

The number of unintended pregnancies is the highest in U.S., which is about 3 million annually. Hence, the Center for Medicaid and CHIP Services (CMCS) established a Maternal and Infant Health Initiative for the Medicaid and Children’s Health Insurance Program (CHIP) to promote use of effective methods of contraception and help women avoid such pregnancies.

IUD segment is expected to witness the fastest growth during the forecast period, attributed to the entry of new devices, availability of long-acting reversible birth control methods, and more than 99.0% effectivity. For instance, in September 2016, Allergan and Medicines360 launched new LILETTA, a levonorgestrel-releasing intrauterine system in U.S. The device is a single handed inserter and for use by women to prevent pregnancy for up to three years.

Further key findings from the study suggest:

  • High demand for contraceptive methods can be attributed to rising awareness about pills and devices, significance of family planning, and presence of supportive government policies improving access to these products
  • In 2018, pills accounted for the largest market share as these product are convenient to use and exhibit more than 99.0% effectivity when accurately consumed. Furthermore, ease of availability, fewer adverse effects, and presence of a large number of players can contribute to this growth
  • North America held the largest market share in 2018 and is anticipated to maintain its dominance during the forecast period due to the presence of major market players, high per capita income, and supportive government initiatives
  • Asia Pacific is estimated to witness the fastest growth in the forthcoming years due to high unmet need, expected increase in coverage in the next 15 years, and increasing number of women in their reproductive age
  • Some of the key players operating in the hormonal contraceptive market are Teva Pharmaceuticals Industries Ltd., Bayer AG, Merck & Co. Inc., Pfizer, Afaxys, Inc., Agile Therapeutics, Allergan, and Apothecus Pharmaceutical Corporation

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Afaxys, Inc.
  • Agile Therapeutics
  • Allergan
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer
  • MORE

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Method
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis (Model 1)
1.6.2 Volume price analysis (model 2)
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1
1.8.2 Objective - 2

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Method
2.2.2 Region
2.3 Competitive Insights

Chapter 3 Market Variables, Trends & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation
3.3 Penetration & Growth Prospect Mapping
3.3.1 Penetration Analysis
3.3.2 Market Driver analysis
3.3.2.1 Rise in government and NGO initiatives to promote contraceptive methods
3.3.2.2 High unmet needs
3.3.3 Market Restraint Analysis
3.3.3.1 Rapidly aging population and rising prevalence of infertility
3.3.3.2 Adverse effects associated with use of contraceptive drugs and devices
3.4 Hormonal Contraceptive Market: Business Environment Analysis Tools
3.4.1 Hormonal Contraceptive Market: Pestle Analysis
3.4.2 Hormonal Contraceptive Market: Porter’s Five Forces Analysis
3.5 Regulatory & Reimbursement Scenario

Chapter 4 Hormonal Contraceptive Market: Method Analysis
4.1 Hormonal Contraceptive Method Market Share Analysis, 2018 & 2026
4.2 Hormonal Contraceptive Method Market: Segment Dashboard:
4.3 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the Method Segment
4.3.1 Pills
4.3.1.1 Pills market, 2015 - 2026 (USD Million)
4.3.2 Intrauterine Devices (IUD)
4.3.2.1 IUD market, 2015 - 2026 (USD Million)
4.3.3 InjecTable
4.3.3.1 InjecTable market, 2015 - 2026 (USD Million)
4.3.4 Vaginal Ring
4.3.4.1 Vaginal ring market, 2015 - 2026 (USD Million)
4.3.5 Implant
4.3.5.1 Implant market, 2015 - 2026 (USD Million)
4.3.6 Patch
4.3.6.1. Patch market, 2015 - 2026 (USD Million)

Chapter 5 Hormonal Contraceptive Market: Regional Analysis
5.1 Hormonal Contraceptive Regional Market Share Analysis, 2018 & 2026
5.2 Hormonal Contraceptive Regional Market: Segment Dashboard
5.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
5.4 Market Size, & Forecasts, and Trend Analysis, 2015 to 2026
5.4.1 North America
5.4.1.1 North America hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.1.1.1 U.S.
5.4.1.1.1.1 U.S. hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.1.1.2 Canada
5.4.1.1.2.1 Canada hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.2 Europe
5.4.2.1 Europe hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.2.1.1 UK
5.4.2.1.1.1 UK hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.2.1.2 Germany
5.4.2.1.2.1 Germany hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.3 Asia Pacific
5.4.3.1 Asia Pacific hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.3.1.1 Japan
5.4.3.1.1.1 Japan hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.3.1.2 China
5.4.3.1.2.1 China hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.4 Latin America
5.4.4.1 Latin America hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.4.1.1 Brazil
5.4.4.1.1.1 Brazil hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.4.1.2 Mexico
5.4.4.1.2.1 Mexico hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.5 Middle East and Africa (MEA)
5.4.5.1 MEA hormonal contraceptive market, 2015 - 2026 (USD Million)
5.4.5.1.1 South Africa
5.4.5.1.1.1 South Africa hormonal contraceptive market, 2015 - 2026 (USD Million)

Chapter 6 Competitive Analysis
6.1 Strategic Framework/Competition Categorization
6.3 Marketing Channels
6.3.1 Direct marketing
6.3.2 Indirect marketing
6.4 Strategy Mapping
6.5 Hormonal Contraceptive Competitive Landscape: Market Position Analysis (Based on products, Market Presence, and Recent Updates/Strategic Initiatives)
6.6 Company Profiles
6.6.1 Allergan
6.6.1.1 Company overview
6.6.1.2 Financial performance
6.6.1.3 service benchmarking
6.6.1.4 Strategic initiatives
6.6.1.5 SWOT analysis
6.6.2 Bayer AG
6.6.2.1 Company overview
6.6.2.2 Financial performance
6.6.2.3 Service benchmarking
6.6.2.4 Strategic initiatives
6.6.2.5 SWOT analysis
6.6.3 Merck & Co., Inc.
6.6.3.1 Company overview
6.6.3.2 Financial performance
6.6.3.3 Service benchmarking
6.6.3.4 Strategic initiatives
6.6.3.5 SWOT analysis
6.6.4 Pfizer
6.6.4.1 Company overview
6.6.4.2 Financial performance
6.6.4.3 Service benchmarking
6.6.4.4 Strategic initiatives
6.6.4.5 SWOT analysis
6.6.5 Afaxys, Inc.
6.6.5.1 Company overview
6.6.5.2 Financial performance
6.6.5.3 Service benchmarking
6.6.5.4 Strategic initiatives
6.6.5.5 SWOT analysis
6.6.6 Teva Pharmaceutical Industries Ltd
6.6.6.1 Company overview
6.6.6.2 Financial performance
6.6.6.3 Service benchmarking
6.6.6.4 Strategic initiatives
6.6.6.5 SWOT analysis
6.6.7 Agile Therapeutics
6.6.7.1 Company overview
6.6.7.2 Financial performance
6.6.7.3 Service benchmarking
6.6.7.4 Strategic initiatives
6.6.7.5 SWOT analysis
6.6.8 Apothecus Pharmaceutical Corp.
6.6.8.1 Company overview
6.6.8.2 Financial performance
6.6.8.3 Service benchmarking
6.6.8.4 Strategic initiatives
6.6.8.5 SWOT analysis

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer
  • Afaxys, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Agile Therapeutics
  • Apothecus Pharmaceutical Corp.
Note: Product cover images may vary from those shown
Adroll
adroll